The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2023 | Turning genomic advances into treatment options
James Spicer, FCRP, PhD, MRCP, MBBS, King’s College London, London, UK, highlights the research being undertaken into the use of existing precision medications for the treatment of lung tumors with less-familiar molecular profiles. Presently, the more accessible and detailed molecular profiling services have enabled the discernment of rarer tumor sub-types, yet many don’t have approved drugs for their treatment. The DETERMINE trial (NCT05722886), an umbrella-basket platform trial, is one such study which aims to record observations from the use of existing targeted therapies in such populations. This interview took place at the British Thoracic Oncology Group (BTOG) Annual Conference 2023 in Belfast, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
King’s College have received funding for recruitment and sponsorship of the CHIRON clinical trial from Achilles Therapeutics.
